Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from the Phase IIb (D1AMOND) Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome

Authors
Category Primary study
JournalNeurology
Year 2024
This article has no abstract
Epistemonikos ID: ad779d1c14a3efbea9e5aed8264a2b2d7e863906
First added on: Feb 19, 2025